top of page
Profile
Join date: Jun 28, 2018
About
0Â likes received
0Â comments received
0Â best answers
Posts (13)
Nov 3, 2021 ∙ 3 min
FDA Grants Profounda Orphan DD Approval for treatment of invasive candidiasis with Miltefosine
FDA Grants Profounda Orphan Drug Designation Approval for treatment of invasive candidiasis with Miltefosine - Invasive candidiasis is an...
919
1524
Oct 6, 2017 ∙ 1 min
ID WEEK in SAN DIEGO
The Profounda team had a booth at this years ID Week convention. Thanks to those that stopped by to learn more about Impavido
390
41
May 9, 2017 ∙ 1 min
AK and miltefosine
Three weeks after treatment with oral miltefosine offers promising hope for patients with AK. Miltefosine is not yet approved for AK but...
657
45
Impavido® (miltefosine) is an FDA-approved treatment for cutaneous, mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO
SITE IS MEANT FOR PHYSICIANS ONLY
Todd MacLaughlan
Admin
More actions
bottom of page